Docket No. 5218-39

## THAT WHICH IS CLAIMED IS:

- 1. A method of reducing endothelial injury in a subject caused by administration of a chemotherapeutic agent to the subject, comprising administering an endothelial-protecting amount of erythropoietin in conjunction with the administration of the chemotherapeutic agent.
- 2. A method according to claim 1 wherein said endothelial-protecting amount of erythropoietin is administered simultaneously with said chemotherapeutic agent.
- 3. A method according to claim 1 wherein said endothelial-protecting amount of erythropoietin is administered prior to said chemotherapeutic agent.
- 4. A method according to claim 1 wherein said endothelial-protecting amount of erythropoietin is administered after said chemotherapeutic agent.
- 5. The method of claim 1 where said chemotherapeutic agent is cisplatin.
- A method of enhancing endothelial cell inhibition in a subject treated with a chemotherapeutic comprising administering to the subject an erythropoietin in endothelial-inhibiting amount of admin**i**stration the with the conjunction chemotherapeutic agent.
- 7. A method according to claim 6 wherein said endothelial-inhibiting amount of erythropoietin is administered simultaneously with said chemotherapeutic agent.

8. A method according to claim 6 wherein said endothelial-inhibiting amount of erythropoietin is administered prior to said chemotherapeutic agent.

- 9. A method according to claim 6 wherein said endothelial-inhibiting amount of erythropoietin is administered after said chemotherapeutic agent.
- 10. A method according to claim 6 wherein said chemotherapeutic agent is cisplatin.
- 11. A method according to claim 6 wherein said subject has a neoplastic growth selected from the group consisting of cerebellar hemangioblastoma, ductal carcinoma of the breast, and squamous cell cancer of the larynx.
- 12. A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering an antineoplastic chemotherapeutic agent in conjunction with an endothelial-inhibiting amount of erythropoietin.
  - 13. A method according to claim 12, wherein said endothelial-inhibiting amount of erythropoietin is administered simultaneously with said chemotherapeutic agent.
  - 14. A method according to claim 12 wherein said endothelial-inhibiting amount of erythropoietin is administered prior to said chemotherapeutic agent.
  - 15. A method according to claim 12 wherein said endothelial-inhibiting amount of erythropoietin is administered after said chemotherapeutic agent.

Docket No.

16. A method of treating endothelial injury caused by mechanical damage, exposure to radiation, inflammation, heart disease or cancer, in a subject in need of such treatment, comprising administering an endothelial-protecting amount of erythropoietin to said subject.